Obsessive-Compulsive Disorder: Strategies to Maximize Opportunities in a Small Market

Published by: Decision Resources

Published: May. 7, 2008 - 24 Pages

Table of Contents

Executive Summary

Strategic Considerations

Stakeholder Implications

Introduction

Overview of Obsessive-Compulsive Disorder

Disease Diagnosis and Symptoms

Etiology

Epidemiology

Current Treatments for Obsessive-Compulsive Disorder

Treatment Algorithm for Obsessive-Compulsive Disorder

FDA-Approved Treatments for Obsessive-Compulsive Disorder

Eli Lilly’s Prozac

GlaxoSmithKline’s Paxil

Pfi zer’s Zoloft

Novartis’s Anafranil

Drugs Used Off-Label to Treat Obsessive-Compulsive Disorder

Forest Laboratories’ Lexapro

SNRIs

Benzodiazepines

Atypical Antipsychotics

2007 U.S. Market

Maximizing the Potential of the Obsessive-Compulsive Disorder Market

Current Dynamics of the Obsessive-Compulsive Disorder Market

Strategies for the Obsessive-Compulsive Disorder Market

Pediatric Approval

Small Clinical Trials

Tables:

1. Agents Commonly Used to Treat Obsessive-Compulsive Disorder

2. U.S. Obsessive-Compulsive Disorder Market, 2007

3. Agents Approved for Other Indications Being Investigated for Effi cacy in Obsessive-Compulsive Disorder, 2008

Figures:

1. Total Prevalent Cases of Obsessive-Compulsive Disorder in the United States, Europe, and Japan, 2007-2017

2. Diagnosed and Drug-Treated Cases of Obsessive-Compulsive Disorder in the United States, Europe, and Japan, 2007

3. Treatment Algorithm for Obsessive-Compulsive Disorder

4. SSRI Action at the Serotonergic Synapse

5. Market Share of Leading Companies in the U.S. Obsessive-Compulsive Disorder Market, 2007

Abstract

• Despite the high use of drug therapy in the treatment of OCD, 40-60% of patients do not achieve suffi cient relief from their symptoms. What opportunities does this unmet need present to developers? Are any agents now in development likely to meet this need?
• Due to the large percentage of patients who are not suffi ciently treated with available approved agents, psychiatrists often prescribe off-label agents to treat OCD. How well do these off-label agents perform in the OCD market? Will pending guidance from the FDA regarding the distribution of data from clinical trials in off-label indications help companies increase their market share for off-label treatments?
• Although there are few agents in commercial development for OCD, there are agents being investigated for their effi cacy in OCD by research and medical organizations. What does the possible infl ux of a large number of new agents to treat OCD mean for currently available treatments? How can emerging agents differentiate themselves from other current and emerging agents?

• Overview of OCD: symptoms and diagnosis, etiology.
• Epidemiology: Decision Resources estimates of the number of prevalent cases of OCD in the major markets over 2007-2017 and the number of diagnosed and drug-treated cases in the major markets in 2007.
• Treatment algorithms: a treatment decision tree, a listing of currently used agents, and profi les of leading agents.
• Use of off-label agents: discussion of agents commonly used off-label, physician attitudes toward off-label use, pending FDA proposals to broaden marketing of these agents.
• OCD market: 2007 sales fi gures, current market dynamics, strategies for maximizing market potential.

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 250,000 market research reports, company profiles and country profiles from over 650 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.